Alpha-9 Oncology | Radiopharmaceuticals | Cancer Therapy
a9oncology.com
Actively hiring
Biotechnology
Oncology Therapeutics
Health Care
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors
Phase 1 study evaluates distinct 225Ac and 177Lu compounds in breast cancer and other solid tumors; data expected in late 2027 225Ac-A9-0642 is the first actinium-based GRPR-targeting compound to enter clinical evaluation with the potential to deliver enh
Read more
Report
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company's imaging agent, A9-3202, which entered the clinic last year
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company's imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., appointed as Chief Medical Officer, bringing extensive clinic
Read more
Report
Alpha-9 Oncology Appoints Paul Blanchfield as Chief Executive Officer
BOSTON, Mass. and VANCOUVER, British Columbia, November 10, 2025 - Alpha-9 Oncology ("Alpha-9" or "the Company"), a clinical-stage radiopharmaceutical company developing targeted cancer therapies, today announced the appointment of Paul Blanchfield as Chi
Read more
Report
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a distin
Read more
Report
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals
BOSTON, Mass. and VANCOUVER, British Columbia, October 23, 2024 - Alpha-9 Oncology Inc. (Alpha-9 or the Company), a clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with cancer, today announced
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~9 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Public Policy
100% ▲
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
1
Countries
2
Busiest office
Boston
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Boston
United States
HQ
Rachit Neupane, PhD
2 open roles 1 posted in 90 days 10-50 est. staff
hires for Public Policy, Early Careers
185 Dartmouth St, 6th Floor, Boston, MA 02116
Vancouver
Canada
HQ
Canada Headquarters
27 E 7th Ave, Suite 300, Vancouver, BC V5T 1M4
San Mateo
United States
Regional office
San Mateo